Announced Tue, 8 Sept, 2026 · 17:37 IST
Subsidiary Deccan Remedies gets drug licence for 6 new products
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.3%1-day move
₹11.50
prior close
₹11.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.5+0.4-0.3-3.3-3.5-11.7-6.3-9.0-10.9-13.9———
Up moveDown movePending
AI summary
Subsidiary Deccan Remedies received approval from AP Drug Control Administration to manufacture 6 new products under Form 25, valid till May 2028. These include Caffeine, Duloxetine, Mebeverine, Phenylephrine, Trimebutine and Oxyclozanide, cleared for domestic and export sale across multiple pharmacopoeia standards. Deccan also secured a 3-year Form 29 Test Licence for 4 more drugs (Ranolazine, Cinnarizine, Sacubitril, Triclabendazole) for research use.
Likely market impact
Expands subsidiary's product range and export capability; positive for diversification but not likely a material near-term trigger.